MOLECULAR PREDICTORS OF RESPONSE TO SELINEXOR IN RECURRENT GLIOBLASTOMA (GBM)

被引：0

作者：

Walker, Christopher ^{[1
]}

Shen, Yao ^{[2
]}

Mau-Soerensen, Morten ^{[3
]}

Wen, Patrick ^{[4
]}

van den Bent, Martin ^{[5
]}

Plotkin, Scott ^{[6
]}

Walenkamp, Annemiek ^{[7
]}

Green, Adam ^{[8
]}

Califano, Andrea ^{[2
]}

Chang, Hua ^{[1
]}

Tamir, Sharon ^{[1
]}

Henegar, Leah ^{[1
]}

Shacham, Sharon ^{[1
]}

Alvarez, Mariano ^{[2
]}

Landesman, Yosef ^{[1
]}

Lassman, Andrew ^{[9
]}

机构：

[1] Karyopharm Therapeut Inc, Newton, MA USA

[2] Darwin Hlth, New York, NY USA

[3] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Erasmus MC Canc Inst, Rotterdam, Netherlands

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Univ Groningen, Groningen, Netherlands

[8] Univ Colorado, Aurora, CO USA

[9] Columbia Univ, New York Presbyterian Hosp, Irving Med Ctr, New York, NY USA

来源：

NEURO-ONCOLOGY | 2020年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BIOM-26

引用

页码：7 / 7

页数：1

共 50 条

[31] Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (Gbm).
Das, A
Badruddoja, M
Tryciecky, D
Yu, J
Black, K
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 132S - 132S
[32] RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
Gilbert, M. R.
Wang, M.
Aldape, K.
Lassman, A.
Sorensen, A. G.
Mikkelson, T.
Groves, M.
Werner-Wasik, M.
Regine, W.
Mehta, M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[33] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
Andre, Jalal
Spearman, Kenneth
Lu, Stanley
Raval, Sumul
NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
[34] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
Andre, J.
Spearman, K.
Lu, S.
Hwang, S.
Dorsett, L.
Raval, S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[35] Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy
Mehrabian, Hatef
Myrehaug, Sten
Soliman, Hany
Sahgal, Arjun
Stanisz, Greg J.
SCIENTIFIC REPORTS, 2018, 8
[36] The glioblastoma (GBM) journey
Lefranc, Florence
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S18 - S18
[37] A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM)
Phuphanich, S.
Rudnick, J.
Chu, R.
Yu, J. S.
Black, K. L.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[38] A phase II trial of lapatinib and pazopanib for patients with recurrent glioblastoma multiforme (GBM)
Reardon, David
Groves, Morris
Wen, Patrick
Nabors, Louis
Mikkelsen, Tom
Rosenfeld, Steve
Harris, Dean
DeMarini, Douglas
Suttle, Ben
Arumugham, Thangam
Hodge, Jeffrey
Lager, Joanne
NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
[39] Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM)
Lassman, A. B.
Iwamoto, F. M.
Gutin, P. H.
Abrey, L. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[40] Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM)
Friedman, H. S.
Desjardins, A.
Vredenburgh, J. J.
Rich, J. N.
Sathornsumetee, S.
Gururangan, S.
Quinn, J. A.
Reardon, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →